Researchers analyzed data on COVID-19 patients from a UK database and compared it to rates of the digestive issues for the individuals after infection, as well as to a control group. They found that 30 days after COVID-19 infection, patients had an increased risk of 41% for gastroesophageal reflux disease; 38% for GI dysfunction; 36% for pancreatic disease; 35% for severe liver disease; 27% for nonalcoholic liver disease; 23% for peptic ulcers; and 21% for gallbladder disease.
“COVID-19 patients are at a higher risk of developing digestive diseases,” the authors of the study from Southern Medical University in Guangzhou, China, wrote. “The risks exhibited a stepwise escalation with the severity of COVID-19, were noted in cases of reinfection, and persisted even after one year follow-up.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
